Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib monotherapy versus ibrutinib plus chlorambucil as first-line treatment for CLL/SLL
ChiCTR2000041420Phase 4Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ibrutinib and chlorambucil in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Ruijin Hospital. Primary endpoint: progression-free survival. Started Dec 2020; status: recruiting.
02
Drugs
ibrutinibchlorambucil
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on ChiCTR2000041420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041420.